Shanghai UniCell Bioengineering Co.

Shanghai UniCell Bioengineering Co.

(Shanghai United Cell Biotechnology Co., Ltd.) was founded in 1995 by the United Pharmaceuticals Group, and its current major investor is High Tide Capital. Shanghai United Cell Biotechnology Co., Ltd. is an industrialized base for research and development, manufacturing and sales of recombinant biologics and vaccines, located in the Biotechnology Park of Shanghai Free Trade Pilot Zone with a registered capital of USD 61.15 million. The company has an annual production capacity of 12.76 million lyophilized powder injections, 13 million water injections in cassette bottles, 10 million capsules and 4 million bags of granules.

With the increase of products, business expansion and production lines in the field of biopharmaceuticals, Shanghai UniCell invested in Zhuhai High-Tech Industrial Development Zone in 2015 to establish Zhuhai UniCell Bioengineering Co. Shanghai UniCell will leverage the strong multinational marketing system built over the past 20 years to achieve the goal of internationalization of Chinese bioengineering products and provide opportunities and resources for the Chinese bioengineering industry to go global.


Ranibizumab Injection VEGF Antibody Fab for multiple VEGF-related ophthalmic indications The original product Lucentis has now been granted for 6 ophthalmic indications, with global sales of Ranibizumab of $3.98 billion and domestic sales of RMB 1.31 billion in 2019, and the overall penetration of anti-VEGF drugs among patients with fundus disease in China was only 0.371 in 2019 TP1T. refer to ICH/OECD-GLP and other international standards for product development.